Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.65 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | DHODH | Q02127 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | KDM6B | O15054 | 1/20 | 0.51 |
| ▸ | KDM4A | O75164 | 1/20 | 0.51 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.51 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168145 | 0.91 | KDM5B (0.66) | KDRKDM5BDHODHKDM4EKDM6B | |
| SCHEMBL30595572 | 0.87 | KDR (0.62) | KDRABCB1KDM4ERETMAP3K20 | |
| SCHEMBL427330 | 0.87 | KDR (0.69) | KDRABCB1RETMAP3K20RIPK3 | |
| SCHEMBL5261234 | 0.87 | KDR (0.62) | KDRABCB1KDM4ERETMAP3K20 | |
| SCHEMBL1715643 | 0.85 | DHODH (0.63) | KDRKDM5BDHODHKDM4E | |
| SCHEMBL1715912 | 0.85 | KDR (0.64) | KDRKDM5BDHODHKDM4E | |
| SCHEMBL31362674 | 0.85 | KDR (0.69) | KDRKDM4E | |
| SCHEMBL6542710 | 0.84 | KDR (0.62) | KDR | |
| SCHEMBL446392 | 0.82 | KDR (0.66) | KDRABCB1KDM4ERETMAP3K20 | |
| SCHEMBL446393 | 0.82 | KDR (0.66) | KDRABCB1RETMAP3K20RIPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112441971-A | Preparation method of apatinib | 郑州大学第一附属医院 | 2021-03-05 | — | — | CN | claimed |
| CN-111233759-A | Process for preparing apatinib | 烟台市烟台山医院 | 2020-06-05 | — | — | CN | claimed |
| CN-110372583-A | A Pa replaces the preparation method of Buddhist nun | 郑州大学第一附属医院 | 2019-10-25 | — | — | CN | claimed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | claimed |
| CN-1906155-A | Novel hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA AS (DK) | 2007-01-31 | — | — | CN | claimed |
| WO-2025024564-A1 | SMALL MOLECULES THAT PREVENT STATIN-INDUCED ACCUMULATION OF HMG COA REDUCTASE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-108467360-B | Preparation method and intermediate of apatinib | 江苏美迪克化学品有限公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-112441971-A | Preparation method of apatinib | 郑州大学第一附属医院 | 2021-03-05 | — | — | CN | disclosed |
| CN-112441971-A | Preparation method of apatinib | 郑州大学第一附属医院 | 2021-03-05 | — | — | CN | disclosed |
| CN-111233759-A | Process for preparing apatinib | 烟台市烟台山医院 | 2020-06-05 | — | — | CN | disclosed |
| CN-111233759-A | Process for preparing apatinib | 烟台市烟台山医院 | 2020-06-05 | — | — | CN | disclosed |
| CN-110372583-A | A Pa replaces the preparation method of Buddhist nun | 郑州大学第一附属医院 | 2019-10-25 | — | — | CN | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| CN-1906155-B | Novel hydroxamic acid ester derivant and pharmaceutical use thereof | LEO PHARMA AS | 2010-06-23 | — | — | CN | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| CN-1906155-A | Novel hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA AS (DK) | 2007-01-31 | — | — | CN | disclosed |
| EP-1697312-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005054179-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | KDR 75/4885KDM5B 972/4885ABCB1 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.